Metabolic profiles of IgA nephropathy, membranous nephropathy, and diabetic nephropathy

Read full text
Authors: Yasin Abdi Saed, lili guo, Rongshan Li
Cited by: 0

Abstract

Introduction: Immunoglobulin A nephropathy (IgAN), membranous nephropathy (MN), and diabetic nephropathy (DN) are prominent contributors to chronic kidney disease burden. Our main objective was to contribute to the understanding of the metabolic profiles of these three major types of nephropathies and identify potential metabolic biomarkers. Material and methods: -test was used to evaluate the statistical significance of the identified metabolites. Metabolic pathways were analyzed using the Kyoto Encyclopedia of Genes and Genomes (KEGG). Specificity, sensitivity, and area under the curve (AUC) were calculated to evaluate the predictive performance of metabolites. Results: Among 557 identified differential metabolites, only 118 were found in all three comparison groups. Differential metabolites of IgAN vs. controls were significantly enriched in arachidonic acid metabolism, starch and sucrose metabolism, ferroptosis, and other pathways. In the DN group, metabolites were mainly enriched in phenylalanine, tyrosine and tryptophan biosynthesis, histidine metabolism, etc. MN-enriched pathways included steroid hormone biosynthesis, neuroactive ligand-receptor interaction, and bile secretion. In the positive mode, cumulative AUC values for comparison pairs IgAN vs. controls, MN vs controls, and DN vs controls were 0.965, 0.972, and 0.573, respectively, whereas in the negative mode the AUC values of all three pairs were slightly above 0.65. Conclusions: IgAN, MN, and DN have similar but distinct metabolic profiles. Only positive node metabolites of IgAN and MN exhibited high predictive performance.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Chronic Kidney Disease and Diabetes Metabolomics and Mass Spectrometry Studies

Publication details

Journal / source
Archives of Medical Science
Volume
22
Issue
4
Pages
2334–2352
Publication date
8 February 2026
Language
EN